An EGFR L858R mutation identified in 1862 Chinese NSCLC patients can be a promising neoantigen vaccine therapeutic strategy

An EGFR L858R mutation identified in 1862 Chinese NSCLC patients can be a promising neoantigen vaccine therapeutic strategy

BackgroundThis study aimed to develop a vaccine that targets mutation-derived neoantigen in Chinese non-small-cell lung cancer (NSCLC).MethodsA cohort of 1862 Chinese NSCLC patients who underwent targeted sequencing with a 1021-gene panel was investigated. HLA typing was done using OptiType v1.0 and...

Full description

Bibliographic Details
Main Authors: Jing Lin, Jun Liu, Shi-guang Hao, Bin Lan, Xiao-bin Zheng, Jia-ni Xiong, Ying-qian Zhang, Xuan Gao, Chuan-ben Chen, Ling Chen, Yu-fang Huang, Hong Luo, Yu-ting Yi, Xin Yi, Jian-ping Lu, Xiong-wei Zheng, Gang Chen, Xue-feng Wang, Yu Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Immunology
Subjects:
EGFR L858R mutation
neoantigen vaccine
HLA A*33:03
immunological features
Chinese NSCLC
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.1022598/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.1022598/full

Similar Items